Breast cancer:: from estrogen to androgen receptor

被引:120
|
作者
Andò, S
De Amicis, F
Rago, V
Carpino, A
Maggiolini, M
Panno, ML
Lanzino, M
机构
[1] Univ Calabria, Dept Pharmacobiol, I-87036 Arcavacata Di Rende, CS, Italy
[2] Univ Calabria, Dept Cell Biol, I-87036 Arcavacata Di Rende, CS, Italy
关键词
breast cancer; estrogen; androgen;
D O I
10.1016/S0303-7207(02)00105-3
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
To investigate the link existing between androgens and human breast cancer, the hormonal milieu present in pre- and postmenopausal women has been translated in an in vitro model utilizing a hormone dependent breast cancer cell line MCF-7 exposed to DHEA, DHEAS, androstenediol, T, DHT with or w/o E-2. DHEAS and androstenediol stimulate the growth of MCF-7 cell line but reduce cell proliferation induced by E-2 (1 nM). T and DHT (1-100 nM) instead inhibit MCF-7 cell proliferation independently on E-2 presence. When we focused our study on the most powerful androgen, DHT alone (100 nM) consistently inhibits MCF-7 cell proliferation by 50% of the basal growth rate and counteracts E-2 proliferative action by 68%. These data correlate well with cell cycle analysis showing an enhanced number of cells in G(0)/G(1) phase after 6 days of DHT treatment. Upon prolonged DHT exposure, Western blotting analysis shows a markedly increased AR content, while immunohistochemistry indicates that it was mostly translocated into the nucleus. So we assumed that the enhanced activation of the AR might inhibit MCF-7 cells proliferation. This assumption is corroborated by the fact that the inhibitory effects induced by DHT on MCF-7 cell proliferation are abrogated in the presence of hydroxyflutamide. Therefore to better investigate the role of AR in inhibiting E-2 action at genomic level, MCF-7 cells were transiently cotransfected with the reporter plasmid XETL carrying firefly luciferase sequence under the control of an estrogen responsive element and the full length AR or with an AR carrying a mutation (Cis 574 --> Arg 574) which abolishes its binding to DNA. The over-expression of the AR markedly decreases E-2 signalling which furthermore appears inhibited by simultaneous exposure to DHT but reversed by addition of hydroxyflutamide. The inhibitory effect was no longer noticeable when MCF-7 cells were cotransfected with XETL and the mutant AR. Taken together these data demonstrate that gonadal androgens antagonize MCF-7 proliferation induced by E-2. This seems to be related to the inhibitory effects of the over-expressed AR on E-2 genomic action. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:121 / 128
页数:8
相关论文
共 50 条
  • [21] Estrogen-dependent breast cancer: The importance of androgen receptor in exemestane treatment
    Amaral, C.
    Augusto, T.
    Roleira, F.
    Tavares-Da-Silva, E.
    Correia-Da-Silva, G.
    Teixeira, N.
    ANNALS OF ONCOLOGY, 2017, 28
  • [22] Androgen receptor and estrogen receptor variants in prostate and breast cancers
    Lopez, Jose C. Valentin
    Lange, Carol A.
    Dehm, Scott M.
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2024, 241
  • [23] Estrogen receptor beta as a novel target of androgen receptor action in breast cancer cell lines
    Rizza, Pietro
    Barone, Ines
    Zito, Domenico
    Giordano, Francesca
    Lanzino, Marilena
    De Amicis, Francesca
    Mauro, Loredana
    Sisci, Diego
    Catalano, Stefania
    Wright, Karin Dahlman
    Gustafsson, Jan-ake
    Ando, Sebastiano
    BREAST CANCER RESEARCH, 2014, 16 (01):
  • [24] Androgen receptor CAG repeat length and estrogen receptor status in postmenopausal breast cancer prognosis
    Cogliati, Patrizia
    Ciniselli, Chiara Maura
    Agresti, Roberto
    Paolini, Biagio
    Bonini, Chiara
    Radice, Paolo
    Krogh, Vittorio
    Verderio, Paolo
    Venturelli, Elisabetta
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2015, 30 (04): : E418 - E424
  • [25] Metabolic differences in estrogen receptor-negative breast cancer based on androgen receptor status
    Noh, Songmi
    Kim, Ji-Ye
    Koo, Ja Seung
    TUMOR BIOLOGY, 2014, 35 (08) : 8179 - 8192
  • [26] Differential impact of the expression of the androgen receptor by age in estrogen receptor-positive breast cancer
    Tokunaga, Eriko
    Hisamatsu, Yuichi
    Taketani, Kenji
    Yamashita, Nami
    Akiyoshi, Sayuri
    Okada, Satoko
    Tanaka, Kimihiro
    Saeki, Hiroshi
    Oki, Eiji
    Aishima, Shinichi
    Oda, Yoshinao
    Morita, Masaru
    Maehara, Yoshihiko
    CANCER MEDICINE, 2013, 2 (06): : 763 - 773
  • [27] Estrogen receptor beta as a novel target of androgen receptor action in breast cancer cell lines
    Pietro Rizza
    Ines Barone
    Domenico Zito
    Francesca Giordano
    Marilena Lanzino
    Francesca De Amicis
    Loredana Mauro
    Diego Sisci
    Stefania Catalano
    Karin Dahlman Wright
    Jan-ake Gustafsson
    Sebastiano Andò
    Breast Cancer Research, 16
  • [28] The Androgen Receptor in Breast Cancer
    Giovannelli, Pia
    Di Donato, Marzia
    Galasso, Giovanni
    Di Zazzo, Erika
    Bilancio, Antonio
    Migliaccio, Antimo
    FRONTIERS IN ENDOCRINOLOGY, 2018, 9
  • [29] Androgen receptor and breast cancer
    Sismondi, P.
    D'Alonzo, M.
    Bounous, V. E.
    Quintili, F.
    Attianese, D.
    San Giorgio, V
    Biglia, N.
    GIORNALE ITALIANO DI OSTETRICIA E GINECOLOGIA, 2014, 36 (01): : 52 - 54
  • [30] Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit β-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer
    Huang, Rui
    Han, Jiguang
    Liang, Xiaoshuan
    Sun, Shanshan
    Jiang, Yongdong
    Xia, Bingshu
    Niu, Ming
    Li, Dalin
    Zhang, Jian
    Wang, Shuo
    Wei, Wei
    Liu, Qing
    Zheng, Wei
    Zhang, Guoqiang
    Song, Yanni
    Pang, Da
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2017, 43 (06) : 2212 - 2225